Evidence map›Paper›PMID 23371351›Full record

ReviewCurrent HIV/AIDS reports2013

Antiretroviral therapy for prevention is a combination strategy.

Margaret L McNairy, Myron Cohen, Wafaa M El-Sadr

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current HIV/AIDS reports, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 37 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Evidence for optimal HIV testing intervals in HIV-negative individuals from various risk groups: a systematic review protocol.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2017
    Review
  7. Canadian and international recommendations on the frequency of HIV screening and testing: A systematic review.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2016
    Article
  8. Frequent HIV Testing: Impact on HIV Risk Among Chinese Men Who Have Sex with Men.Journal of acquired immune deficiency syndromes (1999) · 2016
    Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. A paradigm shift: focus on the HIV prevention continuum.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2014
    Article
  16. Antiretroviral therapy for the prevention of HIV transmission: what will it take?Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2014
    Article
  17. Article
  18. Review
  19. Future of phylogeny in HIV prevention.Journal of acquired immune deficiency syndromes (1999) · 2013
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Margaret L McNairyICAP-Columbia University, Mailman School of Public Health, New York, NY 10032, USA. MM3780@columbia.edu
Myron Cohen
Wafaa M El-Sadr
Columbia University · USUniversity of North Carolina at Chapel Hill · US

Funding

Centers for Innovative Research to Control AIDSUM1AI069466 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI EL-SADR, WAFAA M. · 2012 to 2014
$4.3M
NIAID NIH HHS UM1 AI069466
6 · The paper itself

Abstract

In the past several years, the debate of "treatment vs prevention" has shifted with the introduction of the concept of "treatment as prevention," (TasP), stemming from a series of compelling observational, ecological, and modeling studies as well as HPTN 052, a randomized clinical trial, demonstrating that use of ART is associated with a decrease in HIV transmission. In addition to TasP being viewed as 1 intervention in a combination strategy for HIV Prevention, TasP is, in and of itself, a combination of multiple interventions that need to be implemented with high coverage in order to achieve its potential impact.

Indexed as

Primary PreventionAnti-HIV AgentsCircumcision, MaleCombined Modality TherapyCounselingDrug MonitoringFemaleHealth Services AccessibilityHIV InfectionsHumansInfectious Disease Transmission, VerticalMaleRandomized Controlled Trials as TopicRisk Reduction BehaviorUnited StatesAnti-HIV Agents

Identifiers

PMID23371351
OpenAlexW2046385476

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.